These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 8908675

  • 21. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
    Yoshida M, Kudoh J, Homma Y, Kawabe K.
    Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
    [Abstract] [Full Text] [Related]

  • 22. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM, Klarskov P.
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [Abstract] [Full Text] [Related]

  • 23. Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by the global sympathetic bias that emerges with aging.
    Yun AJ, Doux JD.
    Med Hypotheses; 2006 Apr; 67(2):392-4. PubMed ID: 16427746
    [Abstract] [Full Text] [Related]

  • 24. Medical management of lower urinary tract symptoms in men: current treatment and future approaches.
    Patel AK, Chapple CR.
    Nat Clin Pract Urol; 2008 Apr; 5(4):211-9. PubMed ID: 18301417
    [Abstract] [Full Text] [Related]

  • 25. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J.
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [Abstract] [Full Text] [Related]

  • 26. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T.
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [Abstract] [Full Text] [Related]

  • 27. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.
    Michel MC, Vrydag W.
    Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S88-119. PubMed ID: 16465187
    [Abstract] [Full Text] [Related]

  • 28. Storage and voiding symptoms: pathophysiologic aspects.
    Andersson KE.
    Urology; 2003 Nov; 62(5 Suppl 2):3-10. PubMed ID: 14662401
    [Abstract] [Full Text] [Related]

  • 29. History and nomenclature of alpha1-adrenoceptors.
    Langer SZ.
    Eur Urol; 1999 Nov; 36 Suppl 1():2-6. PubMed ID: 10438241
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Role of alpha blockers in the treatment of BPH: a critical review of clinical results.
    Von Heland M, Casale P.
    Arch Esp Urol; 1994 Nov; 47(9):873-81; discussion 881-2. PubMed ID: 7530943
    [Abstract] [Full Text] [Related]

  • 33. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy.
    Koseoglu H, Aslan G, Ozdemir I, Esen A.
    Urology; 2006 Jun; 67(6):1188-92. PubMed ID: 16750254
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being.
    de Mey C.
    Eur Urol; 1998 Jun; 34 Suppl 2():18-28; discussion 47. PubMed ID: 9732825
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.